×
Hero Background

Lung Cancer Companies

ID: MRFR/HC/0679-CR
200 Pages
Rahul Gotadki
July 2025

Lung cancer is a devastating disease that continues to be a major global health concern. As one of the leading causes of cancer-related deaths worldwide, the search for effective lung cancer therapeutics has prompted numerous pharmaceutical and biotechnology companies to invest heavily in research and development. 

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Lung Cancer Market Research Report - Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Lung Cancer Market

Lung Cancer Therapeutics Key Companies


Latest Lung Cancer Therapeutics Companies Update:

 


AstraZeneca's Tagrisso shows promising results in a Phase III trial: This trial demonstrated Tagrisso's efficacy in treating EGFR-mutated non-small cell lung cancer (NSCLC) with less brain metastases compared to other targeted therapies.


Mirati Therapeutics' investigational drug adavosertib receives Breakthrough Therapy designation from the FDA: This designation recognizes the potential of adavosertib for treating KRAS G12C-mutated NSCLC, a previously difficult-to-treat mutation.


Roche acquires Blueprint Medicines for $3.9 billion: This acquisition strengthens Roche's lung cancer portfolio by adding Blueprint's expertise in targeted therapies for RET-driven cancers, including some lung cancers.


Merck & Co. partners with BeiGene to develop and commercialize tislelizumab: This collaboration expands access to tislelizumab, a promising PD-1 inhibitor, for treating lung cancer and other solid tumors worldwide.


List of Lung Cancer Therapeutics Key companies in the market

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Pfizer (U.S.)

  • Bristol-Myers Squibb (U.S.)

  • Eli Lilly and Company (U.S.)

  • Sanofi (France)